Profound Medical regains exclusive Canadian distribution rights for TULSA-PRO from Knight Therapeutics

Profound Medical Corp.

One-time cash payment of CDN$90,000 (US$64,000) and 5% royalty on Canadian net sales for 15 years.
Only one Canadian site (Sunnybrook Health Sciences Centre) currently offers the TULSA Procedure; >100 procedures performed there.
Plans to use CAPTAIN trial results (comparing TULSA vs robotic prostatectomy) for provincial insurance coverage applications starting 2026.
Regained rights allow Profound to deploy its own direct North American sales team; interim concierge service model for new Canadian sites.
Knight's CEO notes strategic fit: Knight focuses on pharma, while Profound is better suited to commercialize this complex medical device.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.